Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BCAX
SellHot AirBicara Therapeutics Inc. · Healthcare · United States · $1.6B · Avg Vol: $14M/d
COMPANY DESCRIPTION
Bicara Therapeutics Inc. is a clinical-stage biotechnology company developing novel bifunctional therapeutics for cancer treatment. Its unique approach combines targeted drug delivery with immune stimulation, aiming for enhanced efficacy and reduced toxicity. Bicara is a niche biotech focused on innovative oncology drug development with a distinct mechanism of action.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -2.45 | -1.53 | -4.05 | -2.52 | — | -3.07 | -3.38 | -3.47 | — |
| Shares | 51.8M | 51.8M | 54.4M | 56.6M | +9.4% | 66.2M | — | — | — |
| Debt | 0 | 0.7M | 0.7M | 1.7M | 61.3% | 1.2M | — | — | — |
| Equity | -98.8M | -148.8M | 491.9M | 401.5M | -18.4% | — | — | — | — |
| Op CF | -32.1M | -45.6M | -74.8M | -106.8M | — | -134.8M | — | — | — |
| Inv CF | -0.2M | -0.6M | -9.0K | -318.5M | — | — | — | — | — |
| Fin CF | 31.7M | 272.5M | 334.0M | 32.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BCAX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc.(you) | $1.6B | 30 | Sell |
| LBRX | LB Pharmaceuticals Inc | $1.5B | 32 | Sell |
| FBRX | Forte Biosciences, Inc. | $1.6B | 28 | Sell |
| ANRO | Alto Neuroscience, Inc. | $1.4B | 32 | Sell |
| VIR | Vir Biotechnology, Inc. | $1.8B | 29 | Sell |
| ANAB | AnaptysBio, Inc. | $1.7B | 34 | Sell |
| AGIO | Agios Pharmaceuticals, Inc. | $2.0B | 32 | Sell |
| APMD | Apnimed, Inc. | $1.2B | 32 | Sell |
| ZYME | Zymeworks Inc. | $2.0B | 28 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%